Upgrading Azure

Recent developments highlight the impressive long-term earnings potential for this clinical workflow company.

We downgraded our Azure (AZV) recommendation from “buy” to “hold” on August 25, with the share price having increased to 45 cents from 30 cents at our initial “buy” recommendation in March. Since this time, chief executive Robert Grey has sold down about a third of his shareholding, and our confidence in Azure’s long term growth potential has only increased.   

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles